Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of DMX-200 versus placebo on top of ARB therapy in focal segmental glomerulosclerosis
CTR20240758Phase 3Active
- Sponsor
- Dimerix
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of repagermanium in focal segmental glomerulosclerosis (FSGS), sponsored by Dimerix. Started Dec 2024; status: active.
02
Drugs
repagermanium
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on CTR20240758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240758.